PCN244 BUDGETARY IMPACT OF VENETOCLAX WITH RITUXIMAB VERSUS IBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

Abstract

Authors

C. Brito Filho V. Vitale F.M. Vieira

Full Text Cite This Article
Back to Volume 22, Supplemental S3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×